对 "类癌综合征的疗效、安全性和不断发展的医学疗法尚未满足的需求 "的更正

IF 3.3 4区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Neuroendocrinology Pub Date : 2023-12-13 DOI:10.1111/jne.13361

{"title":"对 \"类癌综合征的疗效、安全性和不断发展的医学疗法尚未满足的需求 \"的更正","authors":"","doi":"10.1111/jne.13361","DOIUrl":null,"url":null,"abstract":"\n Koumarianou, A, Daskalakis, K, Tsoli, M, Kaltsas, G, Pavel, M. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. J Neuroendocrinol. 2022; 34(7):e13174. doi:10.1111/jne.13174\n An oversight has occurred in the published version of our paper “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”. Upon review, we have discovered in page 16, 1st line of paragraph 2.6 that we have defined and refer to the abbreviated term 5-HT as 5-hydroxytryptophane, whereas it should be 5-hydroxytryptamine, which is serotonin itself and not a precursor of the neurotransmitter.We sincerely apologize for any confusion this may have caused.","PeriodicalId":16535,"journal":{"name":"Journal of Neuroendocrinology","volume":"36 1","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jne.13361","citationCount":"0","resultStr":"{\"title\":\"Correction to “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”\",\"authors\":\"\",\"doi\":\"10.1111/jne.13361\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n Koumarianou, A, Daskalakis, K, Tsoli, M, Kaltsas, G, Pavel, M. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. J Neuroendocrinol. 2022; 34(7):e13174. doi:10.1111/jne.13174\\n An oversight has occurred in the published version of our paper “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”. Upon review, we have discovered in page 16, 1st line of paragraph 2.6 that we have defined and refer to the abbreviated term 5-HT as 5-hydroxytryptophane, whereas it should be 5-hydroxytryptamine, which is serotonin itself and not a precursor of the neurotransmitter.We sincerely apologize for any confusion this may have caused.\",\"PeriodicalId\":16535,\"journal\":{\"name\":\"Journal of Neuroendocrinology\",\"volume\":\"36 1\",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jne.13361\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuroendocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jne.13361\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jne.13361","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

Koumarianou，A，Daskalakis，K，Tsoli，M，Kaltsas，G，Pavel，M. 类癌综合征的疗效、安全性和不断发展的医学疗法尚未满足的需求。J Neuroendocrinol.2022; 34(7):e13174. doi:10.1111/jne.13174我们的论文《类癌综合征的疗效、安全性和不断发展的医学治疗未满足的需求》的出版版本中出现了疏忽。经审查，我们发现在第 16 页第 2.6 段第 1 行中，我们将 5-HT 定义为 5-hydroxytryptophane 并将其缩写为 5-HT，而它应该是 5-hydroxytryptamine，即血清素本身，而不是神经递质的前体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”

Koumarianou, A, Daskalakis, K, Tsoli, M, Kaltsas, G, Pavel, M. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. J Neuroendocrinol. 2022; 34(7):e13174. doi:10.1111/jne.13174

An oversight has occurred in the published version of our paper “Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome”. Upon review, we have discovered in page 16, 1st line of paragraph 2.6 that we have defined and refer to the abbreviated term 5-HT as 5-hydroxytryptophane, whereas it should be 5-hydroxytryptamine, which is serotonin itself and not a precursor of the neurotransmitter.

We sincerely apologize for any confusion this may have caused.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Neuroendocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

6.20%

发文量

137

审稿时长

4-8 weeks

期刊介绍： Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field. In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.